D3 Bio Completes Series A+ Round to Advance Innovative Oncology Pipeline
Summary
SHANGHAI, April 8, 2024 /PRNewswire/ -- D3 Bio, an emerging global biotechnology company that focuses on discovery, development, and registration of innovative cancer drugs announces its closing of Series A+ financing round led by Medicxi, a leading European life sciences investment firm. This partnership not only validates the potential of our portfolio but also furnishes resources to propel our mission to advance breakthroughs in cancer treatment to transform the lives of patients across the globe." remarked Dr. George Chen, Chairman, and CEO of D3 Bio.Francesco De Rubertis, Co-founder and Partner at Medicxi, commented: "Our mission is to support the innovative genius of entrepreneurs by providing the critical capital, expertise and experience that form the all-important bridge to pharma. "D3 Bio is a globally orientated, clinical stage biotechnology company that focuses on the discovery, development, and registration of new medicines in oncology and immunology. Leveraging deep expertise in drug development and company creation spanning over two decades, Medicxi invests in early and late-stage therapeutics with a product vision that can fulfill a clear unmet medical need.